The Journal. The New Hit Depression Treatment? A Ketamine-Derived Nasal Spray
172 snips
Mar 21, 2025 Explore the transformative journey of Spravato, a nasal spray derived from ketamine, which is revolutionizing treatment for depression. Once struggling after its 2019 approval, it has now surged to over $1 billion in sales. Discover the contrast between recreational use and its groundbreaking potential in mental health care. Personal stories highlight the rapid effects of this innovative treatment, especially for those battling treatment-resistant depression. Delve into the evolving pharmaceutical landscape and the rising acceptance of psychedelics in therapeutic settings.
AI Snips
Chapters
Transcript
Episode notes
Sean's Story
- Sean Fury, a 36-year-old writer, battles treatment-resistant depression.
- He's exploring his mental health struggles through filmmaking, specifically a vampire film.
Depression Treatment Challenges
- Depression is a widespread issue, affecting nearly 30% of U.S. adults.
- Existing antidepressants, like SSRIs, often take weeks to show effects and don't work for everyone.
Ketamine's Potential
- Dr. Hosseini Manji sought a faster-acting depression treatment than SSRIs.
- He found ketamine promising, as it promotes new brain connections and shows rapid effects.